The first U.S. patient has been treated in GRIP 2, a multi-center study evaluating Cartiva’s Synthetic Cartilage Implant (SCI) to treat first carpometacarpal (CMC) joint osteoarthritis at the base of the thumb.
GRIP 2 is comparing SCI to a ligament reconstruction tendon interposition comparator in an estimated 74 patients in the U.S. and U.K.
Cartiva SCI, a hydrogel polymer implant, gained FDA premarket approval to treat great toe arthritis in mid-2016. The procedure is intended to preserve normal joint anatomy, allowing for conventional surgery in the future if needed. The CMC application is available in Canada and the EU.
The first U.S. patient has been treated in GRIP 2, a multi-center study evaluating Cartiva's Synthetic Cartilage Implant (SCI) to treat first carpometacarpal (CMC) joint osteoarthritis at the base of the thumb.
GRIP 2 is comparing SCI to a ligament reconstruction tendon interposition comparator in an estimated 74 patients in the U.S. and...
The first U.S. patient has been treated in GRIP 2, a multi-center study evaluating Cartiva’s Synthetic Cartilage Implant (SCI) to treat first carpometacarpal (CMC) joint osteoarthritis at the base of the thumb.
GRIP 2 is comparing SCI to a ligament reconstruction tendon interposition comparator in an estimated 74 patients in the U.S. and U.K.
Cartiva SCI, a hydrogel polymer implant, gained FDA premarket approval to treat great toe arthritis in mid-2016. The procedure is intended to preserve normal joint anatomy, allowing for conventional surgery in the future if needed. The CMC application is available in Canada and the EU.
Copy to clipboard 
